منابع مشابه
Current peptide HIV type-1 fusion inhibitors.
There are now 26 antiretroviral drugs and 6 fixed-dose combinations, including reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors and fusion (or entry) inhibitors, approved by the US Food and Drug Administration for clinical use. Although they are clinically effective when used in combination, none of the existing drugs are considered ideal because of toxic side effects...
متن کاملPeptide and protein-based inhibitors of HIV-1 co-receptors.
Human immunodeficiency virus (HIV) afflicts an estimated 30 million people globally, making it a continuing pandemic. Despite major research efforts, the rate of new infections has remained relatively static over time. This article reviews an emerging strategy for the treatment of HIV, the inhibition of the co-receptors necessary for HIV entry, CCR5 and CXCR4. The aim of this article is to high...
متن کاملPotent D-peptide inhibitors of HIV-1 entry.
During HIV-1 entry, the highly conserved gp41 N-trimer pocket region becomes transiently exposed and vulnerable to inhibition. Using mirror-image phage display and structure-assisted design, we have discovered protease-resistant D-amino acid peptides (D-peptides) that bind the N-trimer pocket with high affinity and potently inhibit viral entry. We also report high-resolution crystal structures ...
متن کاملRational design of peptide-based HIV proteinase inhibitors.
A series of peptide derivatives based on the transition-state mimetic concept has been designed that inhibit the proteinase from the human immunodeficiency virus (HIV). The more active compounds inhibit both HIV-1 and HIV-2 proteinases in the nanomolar range with little effect at 10 micromolar against the structurally related human aspartic proteinases. Proteolytic cleavage of the HIV-1 gag pol...
متن کاملPeptide inhibitors of the HIV-1 integrase protein
Prof. Assaf Friedler was born in Haifa, Israel, in 1971. He did his undergraduate studies in chemistry at the Hebrew University of Jerusalem, and Ph.D studies in chemistry at the Hebrew University of Jerusalem under the supervision of Prof. Chaim Gilon, in peptide chemistry and medicinal chemistry. After receiving his PhD degree, in 2000, Prof. Friedler moved to Cambridge, UK, to do his post-do...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JAIDS Journal of Acquired Immune Deficiency Syndromes
سال: 2014
ISSN: 1525-4135
DOI: 10.1097/01.qai.0000446702.28977.e1